Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D.

Nat Med. 2019 Nov 4. doi: 10.1038/s41591-019-0628-7. [Epub ahead of print]

PMID:
31686036
2.

Effects of Age and Hearing Loss on the Discrimination of Amplitude and Frequency Modulation for 2- and 10-Hz Rates.

Moore BCJ, Mariathasan S, Sęk AP.

Trends Hear. 2019 Jan-Dec;23:2331216519853963. doi: 10.1177/2331216519853963.

3.

Management of primary hyperparathyroidism in pregnancy: a case series.

McCarthy A, Howarth S, Khoo S, Hale J, Oddy S, Halsall D, Fish B, Mariathasan S, Andrews K, Oyibo SO, Samyraju M, Gajewska-Knapik K, Park SM, Wood D, Moran C, Casey RT.

Endocrinol Diabetes Metab Case Rep. 2019 May 16;2019. pii: EDM190039. doi: 10.1530/EDM-19-0039. [Epub ahead of print]

4.

Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration.

Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML.

Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11701-E11710. doi: 10.1073/pnas.1804506115. Epub 2018 Nov 21.

5.

Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid.

Fong R, Kajihara K, Chen M, Hotzel I, Mariathasan S, Hazenbos WLW, Lupardus PJ.

MAbs. 2018 Oct;10(7):979-991. doi: 10.1080/19420862.2018.1501252. Epub 2018 Aug 23.

6.

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T.

Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.

7.

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.

Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z.

Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594.

8.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A.

Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18. Erratum in: Lancet. 2018 Oct 20;392(10156):1402.

PMID:
29268948
9.

Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections.

Mariathasan S, Tan MW.

Trends Mol Med. 2017 Feb;23(2):135-149. doi: 10.1016/j.molmed.2016.12.008. Epub 2017 Jan 23. Review.

PMID:
28126271
10.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

11.

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, Yu SF, Ng C, Guo J, Liu Y, Fourie-O'Donohue A, Go M, Linghu X, Segraves NL, Wang T, Chen J, Wei B, Phillips GD, Xu K, Kozak KR, Mariathasan S, Flygare JA, Pillow TH.

Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635. Epub 2016 Oct 17.

PMID:
27874860
12.

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice.

Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, Dinoso J, Koppada N, Hong K, Baruch A, Carrasco-Triguero M, Saad O, Mariathasan S, Kamath AV.

MAbs. 2016 Nov/Dec;8(8):1612-1619. Epub 2016 Sep 21.

13.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R.

Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.

14.

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus.

Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S.

Nature. 2015 Nov 19;527(7578):323-8. doi: 10.1038/nature16057. Epub 2015 Nov 4.

PMID:
26536114
15.

PILRα negatively regulates mouse inflammatory arthritis.

Sun Y, Caplazi P, Zhang J, Mazloom A, Kummerfeld S, Quinones G, Senger K, Lesch J, Peng I, Sebrell A, Luk W, Lu Y, Lin Z, Barck K, Young J, Del Rio M, Lehar S, Asghari V, Lin W, Mariathasan S, DeVoss J, Misaghi S, Balazs M, Sai T, Haley B, Hass PE, Xu M, Ouyang W, Martin F, Lee WP, Zarrin AA.

J Immunol. 2014 Jul 15;193(2):860-70. doi: 10.4049/jimmunol.1400045. Epub 2014 Jun 16.

16.

Pillars article: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science. 1994. 264: 703-707.

De Togni P, Goellner J, Ruddle NH, Streeter PR, Andrea F, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J, Russell JH, Karr R, Chaplin DD.

J Immunol. 2014 Mar 1;192(5):2010-4. No abstract available.

17.

Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins.

Hazenbos WL, Kajihara KK, Vandlen R, Morisaki JH, Lehar SM, Kwakkenbos MJ, Beaumont T, Bakker AQ, Phung Q, Swem LR, Ramakrishnan S, Kim J, Xu M, Shah IM, Diep BA, Sai T, Sebrell A, Khalfin Y, Oh A, Koth C, Lin SJ, Lee BC, Strandh M, Koefoed K, Andersen PS, Spits H, Brown EJ, Tan MW, Mariathasan S.

PLoS Pathog. 2013;9(10):e1003653. doi: 10.1371/journal.ppat.1003653. Epub 2013 Oct 10.

18.

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.

Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A.

Oncogene. 2014 Jan 16;33(3):316-25. doi: 10.1038/onc.2012.594. Epub 2013 Jan 14.

PMID:
23318440
19.

Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella.

Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM.

J Exp Med. 2010 Aug 2;207(8):1745-55. doi: 10.1084/jem.20100257. Epub 2010 Jul 5.

20.

Regulation of cytokine-driven functional differentiation of CD8 T cells by suppressor of cytokine signaling 1 controls autoimmunity and preserves their proliferative capacity toward foreign antigens.

Ramanathan S, Dubois S, Gagnon J, Leblanc C, Mariathasan S, Ferbeyre G, Rottapel R, Ohashi PS, Ilangumaran S.

J Immunol. 2010 Jul 1;185(1):357-66. doi: 10.4049/jimmunol.1000066. Epub 2010 Jun 2.

21.

A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide.

Hsu LC, Ali SR, McGillivray S, Tseng PH, Mariathasan S, Humke EW, Eckmann L, Powell JJ, Nizet V, Dixit VM, Karin M.

Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7803-8. doi: 10.1073/pnas.0802726105. Epub 2008 May 29.

22.

ASC, Ipaf and Cryopyrin/Nalp3: bona fide intracellular adapters of the caspase-1 inflammasome.

Mariathasan S.

Microbes Infect. 2007 Apr;9(5):664-71. Epub 2007 Jan 27. Review.

PMID:
17382568
23.

Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation.

Mariathasan S, Monack DM.

Nat Rev Immunol. 2007 Jan;7(1):31-40. Review.

PMID:
17186029
24.

The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection.

Zamboni DS, Kobayashi KS, Kohlsdorf T, Ogura Y, Long EM, Vance RE, Kuida K, Mariathasan S, Dixit VM, Flavell RA, Dietrich WF, Roy CR.

Nat Immunol. 2006 Mar;7(3):318-25. Epub 2006 Jan 29.

PMID:
16444259
25.

Cryopyrin activates the inflammasome in response to toxins and ATP.

Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM.

Nature. 2006 Mar 9;440(7081):228-32. Epub 2006 Jan 11.

PMID:
16407890
26.

Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis.

Mariathasan S, Weiss DS, Dixit VM, Monack DM.

J Exp Med. 2005 Oct 17;202(8):1043-9.

27.

Development of autoreactive diabetogenic T cells in the thymus of NOD mice.

Kwon H, Jun HS, Yang Y, Mora C, Mariathasan S, Ohashi PS, Flavell RA, Yoon JW.

J Autoimmun. 2005 Feb;24(1):11-23. Epub 2004 Dec 8.

PMID:
15725572
28.

Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf.

Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, Roose-Girma M, Erickson S, Dixit VM.

Nature. 2004 Jul 8;430(6996):213-8. Epub 2004 Jun 9.

PMID:
15190255
29.

POPing the fire into the pyrin?

Mariathasan S, Vucic D.

Biochem J. 2003 Jul 1;373(Pt 1):e1-2. Review.

30.

TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR.

Holmberg K, Mariathasan S, Ohteki T, Ohashi PS, Gascoigne NR.

J Immunol. 2003 Sep 1;171(5):2427-34.

31.

Duration and strength of extracellular signal-regulated kinase signals are altered during positive versus negative thymocyte selection.

Mariathasan S, Zakarian A, Bouchard D, Michie AM, Zúñiga-Pflücker JC, Ohashi PS.

J Immunol. 2001 Nov 1;167(9):4966-73.

32.

Regulation of T cell activation, anxiety, and male aggression by RGS2.

Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ, Mariathasan S, Sasaki T, Wakeham A, Ohashi PS, Roder JC, Barnes CA, Siderovski DP, Penninger JM.

Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12272-7.

33.

Degree of ERK activation influences both positive and negative thymocyte selection.

Mariathasan S, Ho SS, Zakarian A, Ohashi PS.

Eur J Immunol. 2000 Apr;30(4):1060-8.

34.

Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.

Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, Penninger JM.

Nature. 2000 Jan 13;403(6766):211-6.

PMID:
10646608
35.

Signals involved in thymocyte positive and negative selection.

Mariathasan S, Jones RG, Ohashi PS.

Semin Immunol. 1999 Aug;11(4):263-72. Review.

PMID:
10441212
36.

Selection of the T cell repertoire.

Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS.

Annu Rev Immunol. 1999;17:829-74. Review.

PMID:
10358775
37.

Vav regulates peptide-specific apoptosis in thymocytes.

Kong YY, Fischer KD, Bachmann MF, Mariathasan S, Kozieradzki I, Nghiem MP, Bouchard D, Bernstein A, Ohashi PS, Penninger JM.

J Exp Med. 1998 Dec 7;188(11):2099-111.

38.

Degree of TCR internalization and Ca2+ flux correlates with thymocyte selection.

Mariathasan S, Bachmann MF, Bouchard D, Ohteki T, Ohashi PS.

J Immunol. 1998 Dec 1;161(11):6030-7.

39.

The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling.

Liu Q, Oliveira-Dos-Santos AJ, Mariathasan S, Bouchard D, Jones J, Sarao R, Kozieradzki I, Ohashi PS, Penninger JM, Dumont DJ.

J Exp Med. 1998 Oct 5;188(7):1333-42.

40.

Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists.

Bachmann MF, Mariathasan S, Bouchard D, Speiser DE, Ohashi PS.

Eur J Immunol. 1997 Dec;27(12):3414-9.

PMID:
9464830
41.

Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation.

Bachmann MF, Oxenius A, Speiser DE, Mariathasan S, Hengartner H, Zinkernagel RM, Ohashi PS.

Eur J Immunol. 1997 Sep;27(9):2195-203.

PMID:
9341759
42.

Biochemical and genetic defects in the DNA-dependent protein kinase in murine scid lymphocytes.

Danska JS, Holland DP, Mariathasan S, Williams KM, Guidos CJ.

Mol Cell Biol. 1996 Oct;16(10):5507-17.

43.

Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice.

Matsumoto M, Lo SF, Carruthers CJ, Min J, Mariathasan S, Huang G, Plas DR, Martin SM, Geha RS, Nahm MH, Chaplin DD.

Nature. 1996 Aug 1;382(6590):462-6.

PMID:
8684487
44.

Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD.

Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3357-61.

45.

Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone.

Shornick LP, De Togni P, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Ferguson TA, Chaplin DD.

J Exp Med. 1996 Apr 1;183(4):1427-36.

46.

Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers.

Matsumoto M, Mariathasan S, Nahm MH, Baranyay F, Peschon JJ, Chaplin DD.

Science. 1996 Mar 1;271(5253):1289-91.

PMID:
8638112
47.

Absence of lymph nodes in lymphotoxin-alpha(LT alpha)-deficient mice is due to abnormal organ development, not defective lymphocyte migration.

Mariathasan S, Matsumoto M, Baranyay F, Nahm MH, Kanagawa O, Chaplin DD.

J Inflamm. 1995;45(1):72-8.

PMID:
7583355
48.

Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin.

De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J, et al.

Science. 1994 Apr 29;264(5159):703-7.

PMID:
8171322

Supplemental Content

Loading ...
Support Center